Hemostemix Inc. (OTCMKTS:HMTXF) (CVE:HEM) Stock Falls After Recent Consolidation
Shares of Hemostemix Inc. (OTCMKTS:HMTXF) (CVE:HEM) ended lower in the previous session after moving in a range over the past month.
Market Stats
On Friday, HMTXF stock decreased 7.73% to $0.1097 with more than 1K shares, compared to its average volume of 3.6k shares. The stock has moved within a range of $0.1097 – 0.1097 after opening trading at $0.1097.
Hemostemix Collaborates with My Next Health, and Gets Subscription USD $150,000 at CAD $0.25 per Unit
Hemostemix Inc. (OTCMKTS:HMTXF) has announced on January 21, 2022, about signing a Global Master Services Agreement with My Next Health (MNH). Hemostemix has also obtained a subscription from MNH (pending approval from TSX Venture Exchange) in the amount of USD $150,000 at CAD $0.25 per Unit.
MNH is focused on improving human health and boosting the global transition to precision medicine. It has completed over 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) till now. Along with its comparison of that database to 60 million patient records, the company has created the world’s first functional genomic AI-based tool that delivers precision medical care.
Needless to say, this tool considerably improves an individual’s health recommendations and clinical trial outcomes. MNH’s algorithms significantly impact clinical trial subject selection. Its functional genomic assays will be incorporated by Hemostemix to complete an assay report by individual. This type of analysis enables Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double blind placebo controlled clinical trial.
Dr. Richard Heinzl, CEO, MNH, is confident about the partnership with Hemostemix, and stated that MNH’s proprietary AI-based genomic and phenotypic tools will surely boost Hemostemix’s cutting-edge personalized stem cell therapeutics.
